New, selective drug targets for treatment of autoimmune and allergic diseases are highly sought. The class of enzymes cyclic nucleotide phosphodiesterases (PDE) have been around for some time as drug targets for treating vascular and inflammatory diseases; however, they have some shortfalls. A novel enzyme PDE8 was recently discovered, and this event will consider attributes of this as a druggable target with value to seed programs to discover new medicines.
At the Bioscience ClubhouseCT event, UCONN Health Center and UCONN Storrs faculty, Drs. Stefan Brocke, Paul Epstein and Kyle Hadden will discuss their proposal to utilize high-throughput screening (HTS) to identify and develop inhibitors of PDE8. Based on their research, such compounds can suppress inflammation in vivo and therefore may serve as a potent and effective therapy to treat a wide range of human autoimmune, autoinflammatory and allergic diseases. The research team brings complementary expertise in inflammation research, drug development and biochemistry to this project. They will share their challenges with science, raising funds, and engaging pharma/biotech as partners.
THANK YOU TO OUR SPONSORS!